JP2008538771A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538771A5
JP2008538771A5 JP2008508062A JP2008508062A JP2008538771A5 JP 2008538771 A5 JP2008538771 A5 JP 2008538771A5 JP 2008508062 A JP2008508062 A JP 2008508062A JP 2008508062 A JP2008508062 A JP 2008508062A JP 2008538771 A5 JP2008538771 A5 JP 2008538771A5
Authority
JP
Japan
Prior art keywords
alkyl
use according
alkynyl
alkenyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CZ2006/000023 external-priority patent/WO2006114064A2/en
Publication of JP2008538771A publication Critical patent/JP2008538771A/ja
Publication of JP2008538771A5 publication Critical patent/JP2008538771A5/ja
Pending legal-status Critical Current

Links

JP2008508062A 2005-04-25 2006-04-25 テロメラーゼのプロセッシビティーを向上させるための化合物の使用 Pending JP2008538771A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67446605P 2005-04-25 2005-04-25
US67523505P 2005-04-27 2005-04-27
US67523405P 2005-04-27 2005-04-27
PCT/CZ2006/000023 WO2006114064A2 (en) 2005-04-25 2006-04-25 Use of compounds to enhance processivity of telomerase

Publications (2)

Publication Number Publication Date
JP2008538771A JP2008538771A (ja) 2008-11-06
JP2008538771A5 true JP2008538771A5 (https=) 2009-05-21

Family

ID=36778204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508062A Pending JP2008538771A (ja) 2005-04-25 2006-04-25 テロメラーゼのプロセッシビティーを向上させるための化合物の使用

Country Status (5)

Country Link
EP (1) EP1879657A2 (https=)
JP (1) JP2008538771A (https=)
AU (1) AU2006239677A1 (https=)
CA (1) CA2606399A1 (https=)
WO (2) WO2006114064A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
ES2874774T3 (es) * 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA201892769A3 (ru) 2013-03-15 2019-08-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
CA2907924C (en) 2013-04-08 2022-10-25 The Board Of Regents Of The University Of Texas System Telomerase mediated telomere altering compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112017005111B1 (pt) 2014-09-15 2023-02-14 The Regents Of The University Of California Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
US10519159B2 (en) 2016-12-22 2019-12-31 Merck Sharp & Dohme Corp. Antiviral aliphatic ester prodrugs of tenofovir
CN108948084B (zh) * 2017-05-19 2020-10-20 浙江司太立制药股份有限公司 替诺福韦双-l-氨基酸酯及其制备方法
IL318465A (en) 2022-07-21 2025-03-01 Antiva Biosciences Inc Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
EP0618214A1 (en) * 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
AU5466500A (en) * 1999-06-04 2000-12-28 Jessie L.S. Au Methods and compositions for modulating drug activity through telomere damage
DE60038038T2 (de) * 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
EP1418241A1 (en) * 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
EP1732569B1 (en) * 2004-01-21 2009-10-14 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Similar Documents

Publication Publication Date Title
JP2008538771A5 (https=)
US12350274B2 (en) Nucleotide analogs
ES2635564T3 (es) Profármaco de tenofovir y usos farmacéuticos del mismo
KR102453808B1 (ko) 필로비리다에 바이러스 감염을 치료하는 방법
AU2016229966B2 (en) Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US11014950B2 (en) Nucleotide analogs
EA038141B1 (ru) Способы лечения вирусных инфекций arenaviridae и coronaviridae
US20160115186A1 (en) Phosphoric acid/phosphonic acid derivatives and medicinal uses thereof
CN114867351B (zh) 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途
Kreemerova Amino acid ester prodrugs of nucleoside and nucleotide antivirals
CN104119385A (zh) 核苷类似物的磷酸酯前药及其应用
HK40060900A (en) Nucleotide analogs
HK1259657A1 (en) Methods for treating filoviridae virus infections
HK1240226B (en) Nucleotide analogs